Literature DB >> 23886643

Bone marrow mononuclear cell transplantation increases metalloproteinase-9 and 13 and decreases tissue inhibitors of metalloproteinase-1 and 2 expression in the liver of cholestatic rats.

Simone Nunes de Carvalho1, Edward Helal-Neto, Daniela Caldas de Andrade, Erika Afonso Costa Cortez, Alessandra Alves Thole, Christina Barja-Fidalgo, Lais de Carvalho.   

Abstract

Liver fibrosis results from chronic injury followed by activation of macrophages and fibrogenic cells like myofibroblasts and activated hepatic stellate cells. These fibrogenic cells express α-smooth muscle actin (α-SMA) and produce excessive extracellular matrix (ECM), with disorganization and loss of function of hepatic parenchyma. It is known that increased levels of metalloproteinases (MMPs) in liver fibrosis are associated with reduction of the pathologic ECM and fibrosis resolution. Recently, it has been shown that bone marrow mononuclear cells (BMMNCs) may reduce collagen and α-SMA expression, and ameliorate liver function in cholestatic rats. Therefore, this study aimed to analyze MMP-2, MMP-9 and MMP-13, and tissue inhibitors of MMPs (TIMPs)-1 and TIMP-2 in the liver of cholestatic rats transplanted with BMMNC. Animals were divided into normal rats, cholestatic rats obtained after 14 and 21 days of bile duct ligation (BDL), and rats obtained after 14 days of BDL that received BMMNCs and were killed after 7 days. MMP and TIMP expression was assessed by Western blotting, along with α-SMA, CD68 and CD11b expression by confocal microscopy. Western blotting analysis showed that 14-day BDL animals had significantly reduced amounts of MMP-2 and MMP-13, but increased amounts of MMP-9 compared to normal rats. After 21 days of BDL, overall MMP amounts were decreased and TIMPs were increased. BMMNC transplantation significantly increased MMP-9 and MMP-13, and decreased TIMP expression. Increased MMP activity was confirmed by zymography. MMP-9 and MMP-13 were expressed by macrophages near fibrotic septa, suggesting BMMNC may stimulate MMP production in fibrotic livers, contributing to ECM degradation and hepatic regeneration.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23886643     DOI: 10.1159/000353215

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  12 in total

1.  Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.

Authors:  Melissa A Linden; Ryan D Sheldon; Grace M Meers; Laura C Ortinau; E Matthew Morris; Frank W Booth; Jill A Kanaley; Victoria J Vieira-Potter; James R Sowers; Jamal A Ibdah; John P Thyfault; M Harold Laughlin; R Scott Rector
Journal:  J Physiol       Date:  2016-05-27       Impact factor: 5.182

2.  Salvianolic acid B prevents steroid-induced osteonecrosis of the femoral head via PPARγ expression in rats.

Authors:  Shuangqing Li; Juan Wang
Journal:  Exp Ther Med       Date:  2016-12-28       Impact factor: 2.447

3.  Intermedin attenuates myocardial infarction through activation of autophagy in a rat model of ischemic heart failure via both cAMP and MAPK/ERK1/2 pathways.

Authors:  Peng Wei; Xiang-Jun Yang; Qiang Fu; Bing Han; Lin Ling; Jie Bai; Bin Zong; Chun-Ying Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

4.  Microsphere-Based Rapamycin Delivery, Systemic Versus Local Administration in a Rat Model of Renal Ischemia/Reperfusion Injury.

Authors:  Jurjen Zandstra; Marike M van Beuge; Johan Zuidema; Arjen H Petersen; Mark Staal; Luisa F Duque; Sergio Rodriguez; Audrey A R Lathuile; Gert J Veldhuis; Rob Steendam; Ruud A Bank; Eliane R Popa
Journal:  Pharm Res       Date:  2015-05-09       Impact factor: 4.200

5.  Cytokines, hepatic cell profiling and cell interactions during bone marrow cell therapy for liver fibrosis in cholestatic mice.

Authors:  Daphne Pinheiro; Luana Leirós; Juliana Barbosa Torreão Dáu; Ana Carolina Stumbo; Alessandra Alves Thole; Erika Afonso Costa Cortez; Carlos Alberto Mandarim-de-Lacerda; Lais de Carvalho; Simone Nunes de Carvalho
Journal:  PLoS One       Date:  2017-11-27       Impact factor: 3.240

Review 6.  Current and Emerging Approaches for Hepatic Fibrosis Treatment.

Authors:  Jingguo Li; Biguang Tuo
Journal:  Gastroenterol Res Pract       Date:  2021-07-16       Impact factor: 2.260

Review 7.  Implication for bone marrow derived stem cells in hepatocyte regeneration after orthotopic liver transplantation.

Authors:  N Pilat; L Unger; G A Berlakovich
Journal:  Int J Hepatol       Date:  2013-09-10

8.  Bone marrow-derived mesenchymal stem cells inhibit the proliferation of hepatic stellate cells by inhibiting the transforming growth factor β pathway.

Authors:  Li-Ting Zhang; Xue-Qin Fang; Qing-Feng Chen; Hong Chen; Ping Xiao; Xue-Bin Peng; Sheng-Xiang Zhang; Jun-Feng Li; Xiao-Rong Mao
Journal:  Mol Med Rep       Date:  2015-09-25       Impact factor: 2.952

9.  Thalidomide Accelerates the Degradation of Extracellular Matrix in Rat Hepatic Cirrhosis via Down-Regulation of Transforming Growth Factor-β1.

Authors:  Peng Lv; Qingshun Meng; Jie Liu; Chuanfang Wang
Journal:  Yonsei Med J       Date:  2015-11       Impact factor: 2.759

Review 10.  Mechanisms Underlying Cell Therapy in Liver Fibrosis: An Overview.

Authors:  Daphne Pinheiro; Isabelle Dias; Karina Ribeiro Silva; Ana Carolina Stumbo; Alessandra Thole; Erika Cortez; Lais de Carvalho; Ralf Weiskirchen; Simone Carvalho
Journal:  Cells       Date:  2019-10-29       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.